Galapagos(US:GLPG) Globenewswire·2025-10-01 20:01Core Viewpoint - Galapagos NV is exploring strategic alternatives for its cell therapy business, including a potential divestiture, to preserve shareholder value [1][3]. Group 1: Strategic Review Process - The Board of Directors has engaged with a wide range of strategic and financial parties to assess interest in acquiring the Cell Therapy Business [2]. - Interested parties have been granted access to a comprehensive data room and confidential presentations from Galapagos management [2]. - A limited number of non-binding offers have been received from consortia, mainly consisting of financial investors [3]. Group 2: Next Steps and Timeline - The Board and management are working with potential bidders to finalize due diligence and explore financing commitments [3]. - A decision on whether to continue with the divestment process or pursue other options is expected after receiving binding offers [4]. - An announcement regarding the outcome of the strategic alternatives review is anticipated by November 5, 2025, coinciding with the release of the third-quarter financial results [4]. Group 3: Company Overview - Galapagos is a biotechnology company focused on addressing high unmet medical needs through innovative science and technology [5]. - The company aims to transform patient outcomes and ensure that its innovations reach those who need them most [5].